Mitchell Glass
Chief Medical Officer & DirectorDr. Mitchell Glass, M.D., is a Director at Q/C Technologies, Inc. (formerly known as TNF Pharmaceuticals, Inc.) (formerly known as MyMD Pharmaceuticals, Inc.) since April 8, 2024 and is its Chief Medical Officer since June 13, 2024 and was its President until 2025. Since August 2013, Dr. Glass is the Chairman of the Board of Accolade Pharmaceuticals LLC and serves as its Chief Executive Officer. He is Chief Executive Officer of Chronic Airway Therapeutics. Dr. Glass is a founder and principal of Medpro Investors, a New York-based venture capital firm focused on the healthcare sector. He serves as the Chief Medical Officer of OrphageniX, Inc. Dr. Glass serves as the President and Chief Executive Officer of Aqumen Pharmaceuticals, NA, Inc., a subsidiary of Aqumen Pharmaceuticals KK. Dr. Glass served as an Executive Vice President of R&D and Chief Medical Officer of Invion Plc. (from August 30, 2012 to February 12, 2019. He has been a Consultant to early stage companies since 2002. He served as Chief Scientific Officer and Senior Vice President of University City Science Center, where he was responsible for identifying, evaluating and commercializing promising technologies. He served as Chief Medical Officer and Senior Vice President of Strategic Drug Development of Atherogenics Inc., from 1997 to 2002. He served as Chief Operating Officer and President of geneRX+, a gene-therapy start-up focused on emphysema. Prior to AtheroGenics, Inc. Since October 2017, Dr. Glass has served as the Chief medical officer of Strados Labs LLC, a privately held medical device and services developer. Since 2010, Dr. Glass has also served as the Manager of Broom Street Associates LLC, a consulting firm to early stage pharmaceutical and medical device companies. Dr. Glass served as Vice President and Director of Cardiopulmonary Clinical Research Development and Medical Affairs of SmithKline Beecham PLC, where he supervised development portfolio in cardiovascular, pulmonary metabolic and renal diseases. Dr. Glass developed the Pulmonary Therapeutics division of ICI Pharmaceuticals (which later became Zeneca) in Wilmington, Delaware and served as its Director for Medical Affairs of Science Center. He served various senior positions with both emerging biotech and large pharmaceutical companies. From 1988 to 1995, Dr. Glass held various positions at ICI Pharmaceuticals PLC, subsequently Zeneca PLC, where he was responsible for developing the pulmonary therapeutics group. He serves as Chairman of the Advisory Board at Apieron, Inc. developer He serves as a Director of OrphageniX, Inc. Dr. Glass served as an Executive Director at Invion Plc. since 2011 until February 12, 2019. He served as Chairman of Pharmaceutical Review Board, Inc. AtheroGenics, Inc. from 1998 to 2002. He served as a Director of geneRX+. From 1985 to 1987, he (Board certified in Pulmonary and Critical Care Medicine) served as an Attending Physician in Pulmonary Medicine and Critical Care at Graduate Hospital, an affiliate of the University of Pennsylvania. His was a postdoctoral Fellow and Research Associate in Pulmonary Medicine and Respiratory Physiology at the University of Pennsylvania. Dr. Glass has a Bachelor of Arts degree in Biology in 1973 and M.D. degree in 1977 at the University of Chicago and completed his Residency in Internal Medicine and Clinical Fellowship in Pulmonary Medicine from Presbyterian, University of Pennsylvania Medical Center. He served as a Member of Scientific Advisory Board of Clinical Advisory Group of Topigen Pharmaceuticals, Inc. since April 2006. Dr. Glass holds an extensive and successful track record in leading companies through FDA regulatory pathways from early research and development to late-stage trials and market commercialization. His career highlights include 5 new drug applications (NDAs) and marketing authorization applications (MAAs), 7 pre-NDA meetings including international counterparts, 12 End of Phase 2 (EOP2) meetings with FDA and more than 80 investigational new drug applications (INDs).
Positions
- Company NameQ/C Technologies, Inc.Stock CodeQCLSPositionChief Medical Officer & Director
